BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.590013140604466
- age_years
- 66
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9E5B5D00-45A2-48A9-9F57-0B4AAE9E4E25 | — | — | 0.985 |
| 2 | 97A8E2B1-059B-4527-8FB4-116F718FFD16 | — | — | 0.981 |
| 3 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.974 |
| 4 | AE67DBFD-0DD0-4F86-A19F-D4789F585A2E | — | — | 0.972 |
| 5 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.967 |
| 6 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.961 |
| 7 | E89DB941-19C3-4CD9-9117-EAAF3B2AFD76 | — | — | 0.955 |
| 8 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.953 |
| 9 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.951 |
| 10 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.616 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.578 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.565 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.533 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.508 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.459 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.441 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.426 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.419 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.413 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.403 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.389 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.367 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.328 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.318 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.303 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |